Sector
Healthcare
Industry
Biotechnology
Employees
87
First IPO Date
June 30, 2000
| Name | Title | Pay | Year Born |
| Selwyn | Chief Executive Officer & Chairman of Executive Management Board | 429,000 | 1971 |
| Ernst-Ludwig Winnacker | Co-Founder & Chairman Scientific Advisory Board | 20,000 | 1941 |
| Dolores J. Schendel | Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development | 470,000 | N/A |
| Pamela Keck | Vice President of Investor Relations & Corporation Communications | 0 | N/A |
| Kirsty Crame | Vice President and Head of Clinical Research & Development | 0 | N/A |
| Birger Kohlert | Chief Financial Officer | 0 | N/A |
Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.